Activation of stimulator of interferon genes in hepatocytes suppresses the replication of hepatitis B virus

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 10, 2017, Pages

  Guo, Fang ^a   Tang, Liudi ^b   Shu, Sainan ^a,c   Sehgal, Mohit ^a   Sheraz, Muhammad ^b   Liu, Bowei ^a,d   Zhao, Qiong ^a   Cheng, Junjun ^a   Zhao, Xuesen ^a   Zhou, Tianlun ^a   Chang, Jinhong ^a   Guo, Ju Tao ^a  

^a BARUCH S BLUMBERG INSTITUTE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Hepatitis B virus; Interferons; STING

Indexed keywords

CIRCULAR DNA; CYCLIC GMP; CYTOKINE; JANUS KINASE 1; SODIUM BILE ACID COTRANSPORTER; VADIMEZAN; VIRUS DNA; ANTIVIRUS AGENT; COTRANSPORTER; INTERFERON; MB21D1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; NUCLEOTIDYLTRANSFERASE; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ANIMAL CELL; ARTICLE; CHRONIC HEPATITIS B; CYTOKINE RESPONSE; GENE; GENE EXPRESSION; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INNATE IMMUNITY; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STABLE EXPRESSION; STIMULATOR OF INTERFERON GENE; VIRUS REPLICATION; AGONISTS; ANIMAL; BIOSYNTHESIS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEP-G2 CELL LINE; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; HEP G2 CELLS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; INTERFERONS; MACROPHAGES; MEMBRANE PROTEINS; MICE; NUCLEOTIDYLTRANSFERASES; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; SYMPORTERS; VIRUS REPLICATION;

EID: 85029754603     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00771-17     Document Type: Article

References (56)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30:2212–2219. https://doi.org/10.1016/j.vaccine.2011.12.116.
2. GBD 2013 Mortality and Causes of Death Collaborators. 2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–171. https://doi .org/10.1016/S0140-6736(14)61682-2.
3. Seeger C, Mason WS. 2015. Molecular biology of hepatitis B virus infection. Virology 479–480:672–686. https://doi.org/10.1016/j.virol.2015.02.031.
4. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049. https://doi.org/10.7554/eLife.00049.
5. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, Sultmann H, Urban S. 2014. Hepatitis B and D viruses exploit sodium taurocholate cotransporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146:1070 –1083. https://doi.org/10.1053/j.gastro.2013.12.024.
6. Guo JT, Guo H. 2015. Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res 122:91–100. https://doi.org/10.1016/j.antiviral.2015.08.005.
7. Chang J, Block TM, Guo JT. 2012. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res 96:405– 413. https://doi.org/10.1016/j.antiviral.2012.10.001.
8. Wieland SF, Chisari FV. 2005. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 79:9369–9380. https://doi.org/10.1128/JVI.79.15.9369-9380.2005.
9. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. 2010. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKand DDX3. J Gen Virol 91:2080 –2090. https://doi.org/10.1099/vir.0.020552-0.
10. Wang H, Ryu WS. 2010. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 6:e1000986. https://doi.org/10.1371/journal.ppat.1000986.
11. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. 2011. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One 6:e15324. https://doi.org/10.1371/journal.pone.0015324.
12. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trepo C, Hasan U, Chemin I. 2011. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 6:e26315. https://doi.org/10.1371/journal.pone.0026315.
13. Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL. 2011. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol 85:987–995. https://doi.org/10.1128/JVI.01825-10.
14. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Wang Y, Wen C, Wu Q, Shi W, Zhong H. 2010. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 185:1158–1168. https://doi.org/10.4049/jimmunol.0903874.
15. Liu Y, Li J, Chen J, Li Y, Wang W, Du X, Song W, Zhang W, Lin L, Yuan Z. 2015. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J Virol 89: 2287–2300. https://doi.org/10.1128/JVI.02760-14.
16. Bertoletti A, Ferrari C. 2012. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61:1754–1764. https://doi.org/10.1136/gutjnl-2011-301073.
17. Thomsen MK, Nandakumar R, Stadler D, Malo A, Valls RM, Wang F, Reinert LS, Dagnaes-Hansen F, Hollensen AK, Mikkelsen JG, Protzer U, Paludan SR. 2016. Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection. Hepatology 64:746–759. https://doi.org/10.1016/j.jhep.2015.11.039.
18. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. 2013. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341:1390–1394. https://doi.org/10.1126/science.1244040.
19. Paijo J, Doring M, Spanier J, Grabski E, Nooruzzaman M, Schmidt T, Witte G, Messerle M, Hornung V, Kaever V, Kalinke U. 2016. cGAS senses human cytomegalovirus and induces type I interferon responses in human monocyte-derived cells. PLoS Pathog 12:e1005546. https://doi.org/10.1371/journal.ppat.1005546.
20. Lam E, Stein S, Falck-Pedersen E. 2014. Adenovirus detection by the cGAS/STING/TBK1 DNA sensing cascade. J Virol 88:974–981. https://doi.org/10.1128/JVI.02702-13.
21. Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, Sun L, Chen ZJ. 2013. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341:903–906. https://doi.org/10.1126/science.1240933.
22. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ. 2013. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339:826 – 830. https://doi.org/10.1126/science.1229963.
23. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786–791. https://doi.org/10.1126/science.1232458.
24. Liu S, Zhao K, Su X, Lu L, Zhao H, Zhang X, Wang Y, Wu C, Chen J, Zhou Y, Hu X, Wang Y, Lu M, Chen X, Pei R. 2017. MITA/STING and its alternative splicing isoform MRP restrict hepatitis B virus replication. PLoS One 12: e0169701. https://doi.org/10.1371/journal.pone.0169701.
25. He J, Hao R, Liu D, Liu X, Wu S, Guo S, Wang Y, Tien P, Guo D. 2016. Inhibition of hepatitis B virus replication by activation of the cGAS-STING pathway. J Gen Virol 97:3368 –3378. https://doi.org/10.1099/jgv.0.000647.
26. Dansako H, Ueda Y, Okumura N, Satoh S, Sugiyama M, Mizokami M, Ikeda M, Kato N. 2016. The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly. FEBS J 283:144–156. https://doi.org/10.1111/febs.13563.
27. Cui X, Clark DN, Liu K, Xu XD, Guo JT, Hu J. 2016. Viral DNA-dependent induction of innate immune response to hepatitis B virus in immortalized mouse hepatocytes. J Virol 90:486–496. https://doi.org/10.1128/JVI.01263-15.
28. Guo F, Han Y, Zhao X, Wang J, Liu F, Xu C, Wei L, Jiang JD, Block TM, Guo JT, Chang J. 2015. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob Agents Chemother 59: 1273–1281. https://doi.org/10.1128/AAC.04321-14.
29. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41: 1715–1720.
30. Tanaka Y, Chen ZJ. 2012. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal 5:ra20. https://doi.org/10.1126/scisignal.2002521.
31. Abe T, Harashima A, Xia T, Konno H, Konno K, Morales A, Ahn J, Gutman D, Barber GN. 2013. STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell 50:5–15. https://doi.org/10.1016/j.molcel.2013.01.039.
32. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE. 2011. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478:515–518. https://doi.org/10.1038/nature10429.
33. Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, Mar KB, Richardson RB, Ratushny AV, Litvak V, Dabelic R, Manicassamy B, Aitchison JD, Aderem A, Elliott RM, Garcia-Sastre A, Racaniello V, Snijder EJ, Yokoyama WM, Diamond MS, Virgin HW, Rice CM. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505:691– 695. https://doi.org/10.1038/nature12862.
34. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT. 2010. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 84:9332–9340. https://doi.org/10.1128/JVI.00918-10.
35. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, Block TM, Guo JT. 2009. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83:847–858. https://doi.org/10.1128/JVI.02008-08.
36. Sussman NL, Chong MG, Koussayer T, He DE, Shang TA, Whisennand HH, Kelly JH. 1992. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 16:60 – 65. https://doi.org/10.1002/hep.1840160112.
37. Mavri-Damelin D, Damelin LH, Eaton S, Rees M, Selden C, Hodgson HJ. 2008. Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 99:644–651. https://doi.org/10.1002/bit.21599.
38. Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT. 2013. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 9:e1003613. https://doi.org/10.1371/journal.ppat.1003613.
39. Sato S, Li K, Kameyama T, Hayashi T, Ishida Y, Murakami S, Watanabe T, Iijima S, Sakurai Y, Watashi K, Tsutsumi S, Sato Y, Akita H, Wakita T, Rice CM, Harashima H, Kohara M, Tanaka Y, Takaoka A. 2015. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42:123–132. https://doi.org/10.1016/j.immuni .2014.12.016.
40. Gallucci L, Kann M. 2017. Nuclear import of hepatitis B virus capsids and genome. Viruses 9:E21. https://doi.org/10.3390/v9010021.
41. Gariano GR, Dell’Oste V, Bronzini M, Gatti D, Luganini A, De Andrea M, Gribaudo G, Gariglio M, Landolfo S. 2012. The intracellular DNA sensor IFI16 gene acts as restriction factor for human cytomegalovirus replication. PLoS Pathog 8:e1002498. https://doi.org/10.1371/journal.ppat.1002498.
42. Summers J, Jilbert AR, Yang W, Aldrich CE, Saputelli J, Litwin S, Toll E, Mason WS. 2003. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A 100:11652–11659. https://doi.org/10.1073/pnas.1635109100.
43. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825–829. https://doi.org/10.1126/science.284.5415.825.
44. Dienstag JL. 2009. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 49:S112–S121. https://doi.org/10.1002/hep.22920.
45. Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL. 2013. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest 123:3728 –3739. https://doi.org/10.1172/JCI68182.
46. Publicover J, Goodsell A, Nishimura S, Vilarinho S, Wang ZE, Avanesyan L, Spolski R, Leonard WJ, Cooper S, Baron JL. 2011. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 121:1154 –1162. https://doi.org/10.1172/JCI44198.
47. Tang L, Zhao Q, Wu S, Cheng J, Chang J, Guo JT. 2017. The current status and future directions of hepatitis B antiviral drug discovery. Expert Opin Drug Discov 12:5–15. https://doi.org/10.1080/17460441.2017.1255195.
48. Corrales L, McWhirter SM, Dubensky TW, Jr, Gajewski TF. 2016. The host STING pathway at the interface of cancer and immunity. J Clin Invest 126:2404–2411. https://doi.org/10.1172/JCI86892.
49. Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. 2017. Innate immune signaling and regulation in cancer immunotherapy. Cell Res 27:96–108. https://doi.org/10.1038/cr.2016.149.
50. Yang D, Liu L, Zhu D, Peng H, Su L, Fu YX, Zhang L. 2014. A mouse model for HBV immunotolerance and immunotherapy. Cell Mol Immunol 11: 71–78. https://doi.org/10.1038/cmi.2013.43.
51. Bility MT, Cheng L, Zhang Z, Luan Y, Li F, Chi L, Zhang L, Tu Z, Gao Y, Fu Y, Niu J, Wang F, Su L. 2014. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog 10:e1004032. https://doi.org/10.1371/journal.ppat.1004032.
52. Guidotti LG, Matzke B, Schaller H, Chisari FV. 1995. High-level hepatitis B virus replication in transgenic mice. J Virol 69:6158–6169.
53. Zhao X, Guo F, Comunale MA, Mehta A, Sehgal M, Jain P, Cuconati A, Lin H, Block TM, Chang J, Guo JT. 2015. Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrob Agents Chemother 59:206 –216. https://doi.org/10.1128/AAC.03999-14.
54. Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H, Cuconati A, Guo H, Chang J, Xu X, Block TM, Guo JT. 2013. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol 87:6931– 6942. https://doi.org/10.1128/JVI.00582-13.
55. Zhang P, Liu F, Guo F, Zhao Q, Chang J, Guo JT. 2016. Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors. Antiviral Res 131:40–48. https://doi.org/10.1016/j.antiviral.2016.04.007.
56. Guo H, Mao R, Block TM, Guo JT. 2010. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol 84:387–396. https://doi.org/10.1128/JVI.01921-09.